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Background and Purpose: Limited evidence suggests that the sphingosine-1-phos-
phate/sphingosine kinase 1 (S1P/SPHK1) signalling pathway is involved in the patho-
genesis of endometriosis. Therefore, we analyzed in this study whether the inhibition
of SPHK1 and, consequently, decreased levels of S1P affected the vascularization
and growth of endometriotic lesions.
Experimental Approach: Endometriotic lesions were surgically induced in the perito-
neal cavity and the dorsal skinfold chamber of female BALB/c mice. The animals
received a daily dose of the SPHK1 inhibitor SKI-5C or vehicle (control). Analyses
involved the determination of lesion growth, cyst formation, microvessel density and
cell proliferation within peritoneal endometriotic lesions by means of high-resolution
ultrasound imaging, caliper measurement, histology and immunohistochemistry. In
the dorsal skinfold chamber model the development of newly formed microvascular
networks and their microhemodynamic parameters within endometriotic lesions
were investigated by means of intravital fluorescence microscopy.
Key Results: SKI-5C significantly inhibited the development and vascularization of
peritoneal endometriotic lesions, as indicated by a reduced growth and cyst forma-
tion, a lower microvessel density and a suppressed cell proliferation, when compared
to vehicle-treated controls. Endometriotic lesions in dorsal skinfold chambers of SKI-
5C-treated animals exhibited a significantly smaller lesion size, lower functional
microvessel density, smaller microvessel diameters and a reduced blood perfusion of
the newly developing microvascular networks.
Conclusions and Implications: SPHK1/S1P signalling promotes the establishment
and progression of endometriotic lesions. The inhibition of this pathway suppresses
the development of endometriotic lesions, suggesting SPHK1 as a potential novel
target for future endometriosis therapy.
Abbreviations: ERα, estrogen receptor-α; ERβ, estrogen receptor-β; FCS, Foetal calf serum; HIF-1α, hypoxia-inducible factor 1-α; S1P, sphingosine-1-phosphate; SKI-5C, 2,2-dimethyl-4S-(1-oxo-
2-hexadecyn-1-yl)-1,1-dimethylethyl ester-3-oxazolidine carboxylic acid; SPHK1, sphingosine kinase-1; SPHK2, sphingosine kinase-2; StaR, steroidogenic acute regulatory protein.
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1 | INTRODUCTION
As a widespread and common disease, endometriosis affects about
5%–10% of women during their reproductive years. Typical symptoms
are dysmenorrhea, chronic pelvic pain and infertility, which
significantly impair the patients' quality of life (Soliman et al., 2016).
Endometriosis is characterized by the occurrence of endometrial
glands and stroma-like tissue outside the uterine cavity (Burney &
Giudice, 2012). Although the disease has been known for a long time,
its aetiology and pathogenesis still remain undefined. In 1927,
Sampson proposed the widely spread theory that shed endometrium
reaches the peritoneal cavity via retrograde menstruation, where it
finally implants at ectopic sites (Sampson, 1927). The further develop-
ment of the ectopic tissue is then crucially dependent on an adequate
blood supply and, hence, the formation of new microvessels
(Groothuis et al., 2005).
Different mechanisms are considered to contribute to the vascu-
larization of endometriotic lesions, including angiogenesis, inoscula-
tion and vasculogenesis (Laschke & Menger, 2018). The formation of
a new microvascular network is mainly driven by hypoxia and modu-
lated by multiple pro- and anti-angiogenic factors (Rocha et al., 2013).
Among them, the pro-angiogenic factor, sphingosine-1-phosphate
(S1P), a bioactive sphingolipid metabolite, is thought to play a major
role in vascular development (Ader et al., 2009). S1P is generated by
two isoforms of sphingosine kinase (SPHK1 and SPHK2) through
phosphorylation of the metabolic precursor sphingosine (Liu
et al., 2002). The activation of SPHK1 is mediated by stimuli such as
VEGF, which initiates endothelial cell sprouting (Ader et al., 2009).
S1P is excreted into the extracellular space via specific transporters,
such as spinster 2 (Nagahashi et al., 2013). Exogenous S1P is a ligand
of five GPCRs, S1P1-5, and regulates essential cellular processes,
including angiogenesis, proliferation, migration, cytoskeletal organiza-
tion, adherence junction assembly and morphogenesis (Sanchez &
Hla, 2004). Intracellularly, S1P functions receptor-independently as
second messenger, affecting calcium homeostasis, cell growth and
apoptosis (Olivera et al., 2003).
Several studies reported a positive effect of the inhibition of
SPHK and the reduction of cellular S1P levels in the treatment of
tumours as well as inflammatory, hyperproliferative and vascular dis-
eases (Datta et al., 2014; Mathews et al., 2010). In addition, decreas-
ing S1P concentrations following the inhibition of SPHK1 have been
shown to attenuate angiogenesis in different pathologies (Ader
et al., 2015; Dai et al., 2017). Moreover, Santulli and co-workers dem-
onstrated that the expression of S1P receptors and enzymes of the
S1P pathway, such as SPHK1, are deregulated in the endometrium
and endometriotic tissue of endometriosis patients (Santulli
et al., 2012). Based on these findings, we analyzed in the present
study whether the targeting of SPHK1 with the specific inhibitor SKI-
5C affects the development and vascularization of endometriotic
lesions in two different mouse models of the disease.
2 | METHODS
2.1 | Animals
All animal care and experimental protocols were approved by the local
governmental animal protection committee (Landesamt für
Verbraucherschutz, Saarbrücken, Germany; permission number:
32/2015) and conducted according to the Directive 2010/63/EU.
Animal studies are reported in compliance with the ARRIVE guidelines
(Percie du Sert et al., 2020) and with the recommendations made by
the British Journal of Pharmacology (Lilley et al., 2020).
As donor animals for the generation of uterine tissue grafts and
as recipient animals for the induction of endometriotic lesions in the
peritoneal cavity and in dorsal skinfold chambers, we used female
BALB/c mice with an age of 12–16 weeks and a weight of 18–25 g
(Institute for Clinical and Experimental Surgery, Saarland University,
Homburg/Saar, Germany). The animals were housed in a conventional
animal facility of the Institute for Clinical and Experimental Surgery,
either 1 (dorsal skinfold chamber model) or 4–6 (peritoneal
What is already known
• Vascularization is a hallmark of endometriosis.
• The sphingosine-1-phosphate signalling pathway is
deregulated in endometriosis.
What does this study add
• The sphingosine kinase-1 inhibitor SKI-5C suppresses the
development of endometriotic lesions.
• Inhibition of sphingosine kinase-1signalling reduces the
formation of new microvascular networks.
What is the clinical significance
• Sphingosine kinase-1 represents a promising pharmaco-
logical target for the treatment of endometriosis.
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endometriosis model) per cage, on wood chips as bedding. They were
maintained under a 12-h day/night cycle and had free access to tap
water and standard pellet food (Altromin, Lage, Germany).
2.2 | Vaginal lavage
In this study, we only included animals with normal oestrous cycles.
The oestrous cycle was evaluated once daily by the cytological analy-
sis of vaginal lavage samples, 1 week prior to the beginning of the
experiments. In brief, 15 μl of 0.9% saline was carefully pipetted into
the vagina. The resulting cell suspension was subsequently transferred
to a glass slide and the cycle stage was determined under a phase con-
trast microscope (CH-2; Olympus, Hamburg, Germany). Only animals
in the stage of oestrus were used as donor and recipient mice for the
transplantation of uterine tissue samples into the peritoneal cavity to
exclude differences between individual animals related to different
sex hormone levels. For the implantation of the dorsal skinfold cham-
ber, mice in the stage of dioestrus were used. After the implantation,
they were allowed to recover for 48 h and, thus, to enter the oestrus
stage. Thereafter, they also received endometrial fragments from
donor mice in the stage of oestrus.
2.3 | Induction of endometriotic lesions
To investigate the effect of SPHK1 inhibition on the development
of endometriotic lesions, a well-established mouse model of endo-
metriosis was used (Rudzitis-Auth et al., 2020). For this purpose,
two uterine tissue samples were sutured to the left and the right
abdominal wall of recipient mice. BALB/c donor mice in the stage
of oestrus were anaesthetized by an i.p. injection of 75 mg kg-1
ketamine and 15 mg kg-1 xylazine. After midline laparotomy, the
uterine horns of the donor mice were isolated and placed into a
petri dish containing DMEM (10% FCS, 100-U ml1 penicillin,
0.1-mg ml1 streptomycin). Subsequently, the uterine horns were
openend longitudinally and 2-mm tissue samples were carefully
removed by means of a dermal biopsy punch (Figure 1a), as
previously described (Rudzitis-Auth et al., 2020).
For the surgical induction of endometriotic lesions, recipient mice
were anaesthetized as described above and after midline laparotomy
the uterine tissue samples were fixed with a 6-0 Prolene suture to the
right and left lateral abdominal wall (Figure 1b,c). The laparotomy was
then closed with running 6-0 Prolene muscle and skin sutures and the
animals received a s.c. injection of 5-mg kg1 carprofen as pain
medication.
F IGURE 1 (a) Longitudinally opened uterine horn of a BALB/c donor mouse with a 2-mm tissue sample (arrow), which was excised by
means of a 2-mm dermal biopsy punch. (b) Fixation of the tissue sample to the abdominal wall of a BALB/c recipient mouse for the
induction of a peritoneal endometriotic lesion (arrow: needle of the Prolene suture). (c) Typical appearance of the transplant (border marked
by broken line) directly after fixation. Scale bars: 2.5 mm. (d–f) HE-stained tissue sections illustrating the preparation of endometrial
fragments, which were transplanted into the dorsal skinfold chamber of BALB/c recipient mice. For this purpose, the perimetrium and
myometrium (in d; shown as #; line = border to the underlying endometrium) were removed from fixed, longitudinally opened uterine horns
by means of microsurgical instruments under a stereo-microscope. Circular tissue fragments (d–f; shown as *, border marked by dotted
line), which only consisted of endometrial stroma and glands (f), were then excised from the underlying endometrium. Scale bars: d,
e = 240 μm; f = 120 μm
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2.4 | High-resolution ultrasound imaging and
analysis
The development of peritoneal endometriotic lesions was repetitively
analyzed with a Vevo 770™ high-resolution ultrasound imaging sys-
tem (VisualSonics, Toronto, ON, Canada) by means of a real-time
microvisualization (RMV™) 704 Scanhead (VisualSonics) with a centre
frequency of 40 MHz and a focal depth of 6 mm (Laschke
et al., 2010). For this purpose, the mice were anaesthetized with 2%
isoflurane in oxygen, fixed in a supine position on a heated stage and
the abdomen was chemically depilated (Nair hair removal lotion;
Church & Dwight Canada Corp., Mississauga, ON, Canada). A three-
dimensional reconstruction and analysis software from VisualSonics
(Vevo 770 V2.3.0) was used to analyze the ultrasound images. To
measure the overall volume of developing endometriotic lesions as
well as the volume of their stromal tissue and cysts (in mm3) by man-
ual image segmentation, boundaries of the lesions and their cysts
were outlined in parallel slices with a step size of 200 μm (Rudzitis-
Auth et al., 2020). Moreover, we calculated the growth of lesions and
stromal tissue (in % of the initial lesion and stromal tissue size)
and assessed the number of cyst-containing lesions (in %).
At the end of the in vivo experiments, the anaesthetized animals
were carefully laparotomized under a stereo-microscope and the
largest (D1) and perpendicularly aligned diameter (D2) of the endo-
metriotic lesions were measured by means of a digital calliper. The
lesion size (S) was then calculated by S = D1 * D2 * π/4 (Becker
et al., 2008). Furthermore, the lesions as well as the ovaries and
uterine horns were harvested and fixed in formalin for additional
histological and immunohistochemical analyses.
2.5 | Dorsal skinfold chamber model
To further investigate the effect of SPHK1 inhibition on the early vas-
cularization of endometriotic lesions, a mouse dorsal skinfold chamber
model was used. This well established model allows the repetitive
monitoring of the newly developing microvasculature in endometriotic
lesions by means of intravital fluorescence microscopy (Laschke
et al., 2011). For this purpose, the two titanium frames of the dorsal
skinfold chamber, sandwiching the dorsal skinfold, were implanted
onto the back of mice in the stage of dioestrus, as described previ-
ously in detail (Laschke et al., 2011). Thereafter, the animals received
a s.c. injection of 5-mg kg1 carprofen as pain medication and were
allowed to recover from anaesthesia and surgical trauma for 48 h
(i.e., until the stage of oestrus). The feeding, cleaning and sleeping
habits as well as the mobility of the mice was not impaired by the
implantation of the dorsal skinfold chamber.
For the generation of endometrial fragments, BALB/c mice in the
stage of oestrus were anaesthetized by i.p. injection of ketamine
(75 mg kg1) and xylazine (15-mg kg1). The two uterine horns were
excised, placed in a petri dish containing DMEM (10% FCS,
100 U ml1 penicillin, 0.1 mg ml1 streptomycin) and opened longitu-
dinally (Figure 1d). Subsequently, the tissue was fixed on a sterile cork
plate and the perimetrium and myometrium were carefully removed
by means of microsurgical instruments under a stereo-microscope
(M651; Leica Microsystems, Wetzlar, Germany) (Figure 1e). From the
underlying endometrium, circular fragments with a diameter of
0.8 mm were then excised (Figure 1f) and stained for 30 s with the
fluorescent dye Hoechst 33342 (200 μg ml1). Thereafter, two
fragments were placed onto the striated muscle tissue within the
observation window of each dorsal skinfold chamber.
2.6 | Intravital fluorescence microscopy
For the analysis of microcirculatory parameters, the vascularization of
the grafted endometrial fragments was observed directly after trans-
plantation (d0) as well as on day 3, 6, 10 and 14 by means of intravital
fluorescence microscopy. For this purpose, the anaesthetized mice
received an i.v. injection of 0.1 ml 5% FITC-labelled dextran
(150,000 Da) into the retrobulbar venous plexus. This enhanced the
blood vessel contrast by staining of the intravascular blood plasma.
The mice were then placed on a plexiglas stage and the newly devel-
oping microvessels were visualized by means of a Zeiss Axiotech
microscope (Zeiss, Oberkochen, Germany) equipped with a 100-W
mercury lamp attached to a filter block for blue, green and UV light.
The microscopic images were recorded by a charge-coupled device
video camera (FK6990; Pieper, Schwerte, Germany) and transferred
to a DVD system for off-line evaluation. The recorded images were
quantitatively analyzed by means of CapImage (version 8.5; Zeintl,
Heidelberg, Germany). This included the determination of the size of
the endometrial fragments (mm2), their functional microvessel density
(cm cm2) as well as the diameters (μm) of 20 individual microvessels
per lesion, their centerline red blood cell (RBC) velocity (μm s1) and
volumetric blood flow (pL s1) (Laschke, Vorsterman van Oijen,
et al., 2011).
2.7 | Histology and immunohistochemistry
Formalin-fixed specimens of peritoneal endometriotic lesions, ovaries
and uterine horns were embedded in paraffin. Sections (3 μm) were
cut and stained with haematoxylin and eosin (HE) according to stan-
dard procedures.
For the immunohistochemical detection of proliferating cells
and hypoxic cells, sections were stained with a rabbit polyclonal
antibody against the proliferation marker Ki67 (1:100) or a rabbit
polyclonal antibody against the hypoxia marker HIF-1α (1:50). A
goat anti-rabbit biotinylated antibody (ready-to-use) followed by
avidin-peroxidase (1:50) or a goat anti-rabbit peroxidase-labelled
antibody (1:100) served as secondary antibody. 3-Amino-
9-ethylcarbazole (AEC Substrate System) was used as chromogen
and counterstaining was performed with hemalaun. The fraction of
proliferating cells and hypoxic cells (%) was assessed by counting
the numbers of Ki67+ and HIF-1α+ cells in four regions of interest
within the tissue.
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For the immunofluorescent detection of microvessels, sections
were stained with a monoclonal rat anti-mouse antibody against the
endothelial cell marker CD31 (1:100). A goat anti-rat IgG Alexa555
antibody served as secondary antibody (1:200). Cell nuclei were sta-
ined with Hoechst 33342 (2 μg ml1). The microvessel density (mm2)
was measured using a BZ-8000 microscope (Keyence, Osaka, Japan).
For this purpose, the overall number of CD31+ microvessels was
counted and divided by the area of stromal tissue.
The Immuno-related procedures used comply with the
recommendations made by the British Journal of Pharmacology
(Alexander et al., 2018).
2.8 | Experimental protocol
In a first set of experiments, a total of 60 uterine tissue samples
(= technical replicates) from 4 donor mice were transplanted into 15
recipient mice (= biological replicates) by fixation of two grafts at the
right and left wall of the abdomen. The animals were divided into two
groups receiving daily either 10 mg kg1 SKI-5C (n = 7) or 0.1-ml corn
oil as vehicle (control; n = 8) by i.p. injection for 28 days. The lower
number of animals in the SKI-5C-treated group was caused by the
death of a mouse during anaesthesia. This dose of SKI-5C has previ-
ously been shown to effectively inhibit the vascularization of breast
cancer xenografts (Datta et al., 2014). Directly after tissue transplan-
tation (d0) as well as on days 7, 14, 21 and 28 the newly developing
endometriotic lesions were analyzed by means of high-resolution
ultrasound imaging. At the end of the in vivo experiments, the size of
the lesions was measured by means of a digital calliper. Subsequently,
the lesions, uterine horns and ovaries were excised for further
histological and immunohistochemical analyses.
In a second set of experiments, a total of 68 uterine tissue sam-
ples (= technical replicates) from four donor mice were transplanted
into 17 recipient mice (= biological replicates), which were treated
daily with either 10 mg kg1 SKI-5C i.p. (n = 9) or vehicle i.p. (control;
n = 8) for 7 days, as described above. The lower number of animals in
the SKI-5C-treated group was caused by the death of a mouse during
anaesthesia. Subsequently, the lesions, uterine horns and ovaries were
excised for further histological and immunohistochemical analyses.
In a third set of experiments, a total of 24 endometrial fragments
(= technical replicates) from four donor mice were transplanted into
the dosal skinfold chambers of 12 recipient mice (= biological repli-
cates), which were treated daily with either 10 mg kg1 SKI-5C i.p.
(n = 6) or vehicle i.p. (control; n = 6) for 14 days, as described above.
Intravital fluorescence microscopy of the grafts was performed
directly after tissue transplantation (d0) as well as on days 3, 6,
10 and 14.
2.9 | Data and statistical analysis
The data and statistical analysis comply with the recommendations
on experimental design and analysis in pharmacology (Curtis
et al., 2018). All experiments were designed to generate groups of
equal size, using randomization and blinded analysis. The statistical
analysis was undertaken only for experiments where each group
size was at least n = 5 of independent values and performed using
these independent values.
The group sizes for the in vivo experiments were chosen
according to previous studies using the herein described endometri-
osis models (Rudzitis-Auth et al., 2020). Data were first analyzed for
normal distribution and equal variance. In case of parametric data, dif-
ferences between two experimental groups were assessed by the
unpaired Student's t test. In case of non-parametric data, differences
between two experimental groups were assessed by the Mann–
Whitney rank sum test (SigmaPlot 13.0; Jandel Corporation, San
Rafael, CA, USA, RRID:SCR_003210). All data are given as mean ±
SEM. Statistical significance was accepted for P < 0.05.
2.10 | Materials
SKI-5C (2,2-dimethyl-4S-(1-oxo-2-hexadecyn-1-yl)-1,1-dimethylethyl
ester-3-oxazolidinecarboxylic acid), corn oil, FITC-labeledlabelled
dextran, Hoechst 33342 were from Sigma-Aldrich (Taufkirchen,
Germany). DMEM was from PAN-Biotech (Aidenbach, Germany).
FetalFoetal calf serum (FCS), penicillin and streptomycin were from
Biochrom (Berlin, Germany). Ketamine was from Serumwerke
Bernburg (Bernburg, Germany). Xylazine was from Bayer AG
(Leverkusen, Germany). Rimadyl (carprofen) was from Zoetis Deutsch-
land GmbH (Berlin, Germany). Dorsal skinfold chambers were from
Irola Industriekomponenten GmbH & Co. KG (Schonach, Germany).
Dermal biopsy punches were from Stiefel Laboratorium GmbH
(Offenbach am Main, Germany). Prolene sutures were from Ethicon
Products (Norderstedt, Germany). The monoclonal rat anti-mouse
antibody against CD31 (Cat# DIA-310, RRID:AB_2631039) was from
Dianova (Hamburg, Germany) and its corresponding goat anti-rat IgG
Alexa555 secondary antibody (Cat# A-21434, RRID:AB_2535855)
was from Thermo Fisher Scientific (Dreieich, Germany). The rabbit
polyclonal antibody against Ki67 (Cat# ab15580, RRID:AB_443209)
and its corresponding goat anti-rabbit biotinylated secondary antibody
(Cat# ab64256, RRID:AB_2661852), the rabbit polyclonal
antibody against hypoxia-inducible factor (HIF)-1α (Cat# ab114977,
RRID:AB_10900336) and its corresponding goat anti-rabbit
peroxidase-labeledlabelled secondary antibody (Cat# 111-035-04,
RRID:AB_2307391) as well as 3-amino-9-ethylcarbazole (AEC Sub-
strate System; Cat# ab64252, RRID:AB_2336076) were from Abcam
(Cambridge, UK).
2.11 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in the IUPHAR/BPS Guide to PHARMACOL-
OGY (http://www.guidetopharmacology.org) and are permanently
archived in the Concise Guide to PHARMACOLOGY 2019/20
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(Alexander, Christopoulos, et al., 2019; Alexander, Cidlowski,
et al., 2019; Alexander, Fabbro, et al., 2019a, 2019b; Alexander, Kelly,
et al., 2019a, 2019b).
3 | RESULTS
3.1 | Growth and cyst formation of endometriotic
lesions
The development of peritoneal endometriotic lesions was analyzed by
means of repetitive high-resolution ultrasound imaging throughout an
observation period of 28 days (Figure 2a,b). Directly after the trans-
plantation of uterine tissue samples from donor mice to the abdominal
wall of recipient animals, the grafts exhibited a comparable initial size
of 1.5 mm3 in the vehicle- and the SKI-5C-treated group (Figure 2c).
During the following time course, the volume of newly developing
endometriotic lesions in the vehicle-treated mice progressively
increased, whereas the lesion growth in the SKI-5C-treated animals
was significantly suppressed (Figure 2c,d). Accordingly, SKI-5C-
treated lesions also presented with a reduced stromal tissue volume
and stromal tissue growth on days 21 and 28 when compared to con-
trols (Figure 2e,f). Moreover, their cyst volume was markedly reduced
at the end of the 28-days observation period, while the final fraction
F IGURE 2 (a,b) High-
resolution ultrasound imaging of
newly developed endometriotic
lesions (border marked by broken
line, cyst-like dilated endometrial
glands marked by dotted line)
28 days after transplantation of
uterine tissue samples to the
abdominal wall of a vehicle-
treated control (a) and a SKI-5C-
treated BALB/c mouse (b). Scale
bars: a, b = 1 mm. (c–h) Overall
lesion volume (c, mm3), lesion
growth (d, %), stromal tissue
volume (e, mm3), stromal tissue
growth (f, %), cyst volume (g,
mm3) and fraction of cyst-
containing lesions (h, %) of
endometriotic lesions in vehicle-
treated controls (n = 8) and SKI-
5C-treated BALB/c mice (n = 7),
as assessed by high-resolution
ultrasound imaging on days 7, 14,
21 and 28. Data shown are
individual values with means ±
SEM. *P < 0.05, significantly
different from control
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of cyst-containing lesions was comparable in both groups (Figure 2g,
h). In line with these results, additional histological analyses on day
28 revealed that SKI-5C-treated endometriotic lesions also contained
smaller cyst-like dilated glands (Figure 3a,b). Moreover, they exhibited
a significantly lower caliper-assessed lesion size when compared with
vehicle-treated controls (Figure 3c).
3.2 | Vascularization and cell proliferation of
endometriotic lesions
Immunohistochemical analyses revealed a significantly lower density
of CD31+ microvessels within SKI-5C-treated peritoneal endo-
metriotic lesions on day 7 when compared to vehicle-
treated controls (Figures 4a, 4b and 4m). In contrast, the lesions of
both groups exhibited a comparable microvessel density on
day 28 (Figures 4c, 4d and 4m). These results demonstrate
that the blockade of SPHK1 inhibits the formation of new micro-
vascular networks, particularly in the early phase of lesion
development.
In addition, we found that vehicle- and SKI-5C-treated lesions
contained a comparably high number of proliferating Ki67+ stromal
and glandular cells on day 7 (Figures 4e, 4f and 4n). On day
28, the lesions of both groups exhibited markedly lower numbers
of proliferating stromal and glandular cells (Figure 4n). Moreover,
stromal cell proliferation was significantly reduced in SKI-5C-
treated lesions at this late time point when compared to vehicle-
treated controls (Figures 4g, 4h and 4n). Finally, we only detected
a low fraction of HIF-1α+ stromal cells on day 7 and 28, which
did not significantly differ between the two groups (Figures 4i–l
and 4o).
3.3 | Effect of SPHK1 inhibition on the female
reproductive organs
To detect potential side effects of SPHK1 inhibition on the female
reproductive organs, we additionally analyzed the vascularization and
proliferation within the ovaries and uterine horns of vehicle- and SKI-
5C-treated animals on day 7 and 28 after the surgical induction of
endometriotic lesions. Notably, there were no significant differences
in the microvessel density and the number of proliferating cells
between the two groups (Figure 5a–k).
3.4 | Early vascularization of endometriotic lesions
in the dorsal skinfold chamber
Finally, we used the dorsal skinfold chamber model to analyze the
effect of SPHK1 inhibition on the early vascularization of endo-
metriotic lesions by means of intravital fluorescence microscopy. This
approach does not only allow the assessment of the morphology of
newly developing microvascular networks, but also the measurement
of microhaemodynamic parameters (Laschke, Vorsterman van Oijen,
et al., 2011). Consistent with the results of our peritoneal
endometrosis model, we found that the treatment with SKI-5C
suppressed the growth of newly developing endometriotic lesions
during the observation period of 14 days (Figure 6a–c). In addition,
endometriotic lesions in SKI-5C-treated mice exhibited a significantly
lower functional microvessel density between day 6 to day 14, when
compared with the lesions in vehicle-treated control animals
(Figures 6a, 6b and 6d). Moreover, microvessels within SKI-5C-treated
lesions presented with significantly smaller diameters and a reduced
volumetric blood flow on day 10 (Table 1).
F IGURE 3 (a,b) HE-stained endometriotic
lesions (border marked by broken line, cyst-like
dilated endometrial glands marked by dotted line,
asterisk = suture) 28 days after transplantation of
uterine tissue samples to the abdominal wall of a
vehicle-treated control (a) and a SKI-5C-treated
BALB/c mouse (b). Scale bars: a, b = 250 μm. (c)
Lesion size (mm2) of endometriotic lesions in
vehicle-treated controls (n = 8) and SKI-5C-
treated BALB/c mice (n = 7), as assessed by
caliper measurements. Data shown are individual
values with means ± SEM. *P < 0.05, significantly
different from control
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4 | DISCUSSION
An increasing number of studies suggests that sphingolipids, such as
S1P, are involved in the pathogenesis of endometriosis. In fact, S1P
promotes the growth of endometriotic cells through the
overexpression of IL-6 a pro-inflammatory cytokine associated with
the establishment of endometriotic lesions (Bergqvist et al., 2001).
Moreover, the expression of several enzymes involved in the cellular
maintenance of balanced S1P levels is deregulated in endometriotic
lesions (Santulli et al., 2012). This mainly affects enzymes responsible
F IGURE 4 (a–d) Immunofluorescent detection of CD31+ microvessels (arrows) on day 7 and 28 after transplantation of uterine tissue
samples to the abdominal wall of vehicle-treated controls and SKI-5C-treated BALB/c mice. Scale bars: 40 μm. (e–h) Immunohistochemical
detection of proliferating Ki67+ stromal cells (arrows) and glandular epithelial cells (arrowheads) on day 7 and 28 after transplantation of uterine
tissue samples to the abdominal wall of vehicle-treated controls and SKI-5C-treated BALB/c mice. Scale bars: 40 μm. (i–l) Immunohistochemical
detection of hypoxic HIF-1α+ stromal cells (arrows) on day 7 and 28 after transplantation of uterine tissue samples to the abdominal wall of
vehicle-treated controls and SKI-5C-treated BALB/c mice. Scale bars: 40 μm. M: Microvessel density (mm2) of endometriotic lesions in vehicle-
treated controls (n = 8–9) and SKI-5C-treated BALB/c mice (n = 7–9), as assessed by immunohistochemistry. Data shown are individual values
with means ± SEM. *P < 0.05, significantly different from control. N: Ki67+ cells (%) within the stroma and the glands of endometriotic lesions in
vehicle-treated controls (n = 8–9) and SKI-5C-treated BALB/c mice (n = 7–9), as assessed by immunohistochemistry. Data shown are individual
values with means ± SEM. *P < 0.05, significantly different from control O: HIF-1α+ cells (%) within the stroma of endometriotic lesions in
vehicle-treated controls (n = 8) and SKI-5C-treated BALB/c mice (n = 7–9), as assessed by immunohistochemistry. Data shown are individual
values with means ± SEM
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for the inactivation of S1P, resulting in an accumulation of the
sphingolipid within the cells. S1P, in turn, acts as a chemoattractant
for endothelial cells via the S1P1 receptor and stimulates their prolif-
eration and migration (Hla et al., 2001). Furthermore, the activation of
S1P1 receptors by S1P maintains the vascular stability and barrier
function during blood vessel development (Hisano & Hla, 2019). In
contrast, inhibition of SPHK1 and, consequently, low levels of endog-
enous S1P provoke an endothelial hypersprouting phenotype in vitro
(Gaengel et al., 2012). This is associated with the insufficient
recruitment of mural cells, which results in a malformation of the
microvasculature. Accordingly, several studies indicate that the
pharmacological inhibition of SPHK1 suppresses the development of
functional microvascular networks in different pathological conditions
(Ader et al., 2015; Dai et al., 2017). As angiogenesis has been identi-
fied as a major prerequisite for the establishment and progression of
endometriotic lesions inside the abdominal cavity, anti-angiogenic
approaches have been suggested as a potential treatment strategy in
the management of endometriosis (Bedaiwy et al., 2017). Consistent
with this view, we could demonstrate in the present study that block-
ade of SPHK1 by the low MW inhibitor SKI-5C inhibited the vascular-
ization and growth of newly developing endometriotic lesions.
For our study, we used a well-established mouse model of perito-
neal endometriosis (Kiani et al., 2019; Rudzitis-Auth et al., 2020). In
this model, endometriotic lesions are surgically induced by trans-
planting uterine tissue samples from donor mice to the abdominal wall
of syngeneic recipient animals. Although this is a widely used model in
endometriosis research, which has been proven to be suitable for the
assessment of pharmacological effects on endometriotic lesions, it has
to be considered that it does not involve the use of pathological endo-
metriotic tissue derived from humans. Accordingly, the results
obtained in the present study may not fully relate to human patients
with endometriosis. In fact, human endometriotic lesions originate
from menstruated endometrial tissue, while mice do not menstruate
and, thus, do not develop spontaneous endometriosis. To overcome
F IGURE 5 (a–h) Immunohistochemical detection of CD31+ microvessels (a–d) and proliferating Ki67+ cells (e–h) in the ovaries (a, b, e and f)
and uterine horns (c, d, g and h) on day 28 after transplantation of uterine tissue samples to the abdominal wall of vehicle-treated controls (a, c, e
and g) and SKI-5C-treated (b, d, f and h) BALB/c mice. Scale bars: 80 μm. (i) Microvessel density (mm2) of the ovaries and uterine horns in
vehicle-treated controls (n = 7–9) and SKI-5C-treated BALB/c mice (n = 7–9), as assessed by immunohistochemistry. Mean ± SEM. J, K: Ki67+
cells (%) within the stroma and the follicles of the ovaries (j) as well as the stroma and glands of the uterine horns (k) in vehicle-treated controls
(n = 7–9) and SKI-5C-treated BALB/c mice (n = 7–9), as assessed by immunohistochemistry. Data shown are individual values with means ± SEM
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this problem, novel approaches have recently been established to
induce decidualization of the endometrium in mice (Peterse
et al., 2018). Greaves et al. (2014, 2017) found that endometriotic
lesions originating from decidualized mouse endometrium exhibit
many similarities to human endometriotic lesions regarding expression
of oestrogen receptors, inflammation, macrophage infiltration and
pain induction. Nonetheless, even the direct transfer of findings from
such menstruating mouse models to the human situation is
questionable, because the signalling processes involved in
decidualization are different in both species (Ramathal et al., 2010).
Our ultrasound analyses revealed that the lesions in vehicle-
treated control mice progressively grow during the observation period
of 28 days, whereas lesion growth is significantly inhibited in SKI-5C-
treated animals. To clarify whether this was caused by hypoxia
resulting from the impaired vascularization of SKI-5C-treated lesions,
we performed immunohistochemical staining of the lesions with the
F IGURE 6 (a,b) Intravital fluorescent
microscopic images of newly developed
endometriotic lesions (borders marked by broken
line) on day 10 after transplantation of
endometrial fragments into the dorsal skinfold
chamber of a vehicle-treated control (a) and a SKI-
5C-treated BALB/c mouse (b). Scale bars: 175 μm.
(c,d) Lesion size (mm2; c) and functional
microvessel density (FMD; cm cm2; d) of
endometriotic lesions in dorsal skinfold chambers
of vehicle-treated controls (n = 6) and SKI-5C-
treated BALB/c mice (n = 6), as assessed by
intravital fluorescence microscopy. Data shown
are individual values with means ± SEM. *P < 0.05,
significantly different from control
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well-established hypoxia marker HIF-1α. Of interest, we found that
the lesions of both groups contained only a very low fraction of hyp-
oxic stromal cells on day 7 and 28 after induction. This finding implies
that other mechanisms than hypoxia must have been involved in
mediating the inhibitory effects of the SPHK1 inhibitor SKI-5C on
lesion growth and stromal cell proliferation. In this context, it has
already been reported that the inhibition of S1P signaling, via S1P1
and S1P3 receptors, directly suppresses the proliferation of endome-
trial stromal cells (Yoshino et al., 2019). Moreover, Datta et al. (2014)
found that SKI-5C increases cell cycle arrest in the G1 phase in triple-
negative breast cancer cells, which is associated with a decreased
phosphorylation of ERK1/2 and Akt. Additional studies in tumour cell
lines and breast epithelial cells indicate that the anti-proliferative
effect of SPHK1 inhibition may also be caused by a reduced expres-
sion of NF-κB (Li et al., 2014, 2016). In endometriotic lesions, NF-κB
activation enhances cell proliferation and survival (González-Ramos
et al., 2010). Conversely, inhibition of NF-κB has been shown to sup-
press DNA synthesis and to induce apoptosis and cell cycle arrest in
endometriotic stromal cells by inhibiting the phosphorylation of the
IκB protein, resulting in the regression of endometriotic lesions in vivo
(González-Ramos et al., 2008; Nasu et al., 2007).
In addition, recent studies suggest that S1P increases COX-2
mRNA expression and, thus, enhances the secretion of PGE2
(Rumzhum et al., 2016). SPHK1 deficiency, in turn, is associated with
a reduced COX-2 expression (Furuya et al., 2017). These are interest-
ing observations considering the fact that COX-2/PGE2 signalling has
been shown to regulate the secretory activity of endometrial glands
(Rudzitis-Auth et al., 2018). Moreover, others have demonstrated that
SPHK1 is localized in glandular epithelial cells and that the concentra-
tion of S1P is increased in the cyst fluid of endometriomas (Yoshino
et al., 2019). In line with these findings, we found significantly lower
cyst volumes in endometriotic lesions of SKI-5C-treated mice when
compared with controls.
The maintenance and formation of adherence junctions in the
microvasculature is mediated by S1P-induced activation of S1P1
receptors (Blaho & Hla, 2014). Moreover, S1P promotes endothelial
cell migration and VEGF-induced vessel formation (Lee et al., 1999).
In addition, S1P1 receptors are necessary for the stabilization of blood
vessels. Hence, knock-down of this receptor causes extensive vascular
haemorrhages and a lethal phenotype in mice lacking S1P1 receptors
(Liu et al., 2000). The same effects are observed in SPHK1- and
SPHK2-double knockout mice (Mizugishi et al., 2005). This indicates
that S1P represents a promising target for anti-angiogenic therapy.
Accordingly, the treatment with a specific monoclonal antibody
against S1P inhibited vessel formation and induced tumour regression
in multiple murine cancer models (Visentin et al., 2006). In vitro and
in vivo assays revealed that this was associated with a reduced release
of the pro-angiogenic factors IL-6, IL-8 and VEGF (O'Brien
et al., 2009; Visentin et al., 2006). Thus, it is possible that these mech-
anisms also caused the lower microvessel density within SKI-5C-
treated endometriotic lesions, compared with vehicle-treated controls,
that we detected here. Of interest, this effect of SPHK1 inhibition
was only observed on day 7. This may be explained by the fact that in
the present experimental setting, the uterine tissue grafts lack their
own blood supply and, thus, suffer from hypoxia until day 3 after
transplantation (Laschke, Giebels, et al., 2011). Hypoxia, in turn, is a
major trigger for the cellular release of S1P (Ader et al., 2009). Hence,
the anti-angiogenic action of SKI-5C on endometriotic lesions may be
mainly effective in the early phase of lesion development. Taking this
into account, future clinical treatment with a SPHK1 inhibitor may be
particularly suitable to suppress the establishment of new
endometriotic lesions with a high angiogenic activity after surgical
treatment, preventing the recurrence of the disease.
In an additional set of experiments, we analyzed the early vascu-
larization of endometriotic lesions in the dorsal skinfold chamber
model. This model allows the repetitive in vivo assessment of mor-
phological and microhaemodynamic parameters during the formation
of new microvascular networks within the same animals over time,
which markedly reduces the number of animals required for the
analysis, thus complying with the 3Rs principles (Laschke, Vorsterman
van Oijen, et al., 2011). Transplanted endometrial fragments
progressively grew in vehicle-treated control mice, whereas the grafts
in SKI-5C-treated animals even decreased in size over time.
Furthermore, the functional microvessel density of SKI-5C-treated
TABLE 1 Diameter, centerline RBC
velocity and volumetric blood flow of
individual microvessels within
endometriotic lesions in dorsal skinfold
chambers of vehicle-treated controls
(n = 6) and SKI-5C-treated BALB/c mice
(n = 6), as assessed by intravital
fluorescence microscopy and computer-
assisted image analysis throughout an
observation period of 14 days
d3 d6 d10 d14
Diameter (μm)
Control 16.8 ± 1.2 15.4 ± 0.6 16.0 ± 1.2* 15.1 ± 0.9*
SKI-5C 18.4 ± 0.4* 15.0 ± 1.0 12.6 ± 0.7* 12.8 ± 1.2
Centerline RBC velocity (μm s1)
Control 122.1 ± 19.5 223.3 ± 43.0 187.8 ± 39.3 180.5 ± 32.4
SKI-5C 75.6 ± 25.9 103.0 ± 17.5 158.3 ± 29.8 176.4 ± 39.0
Volumetric blood flow (pL s1)
Control 20.1 ± 3.5 28.1 ± 4.9 30.3 ± 6.4 28.8 ± 7.8
SKI-5C 23.0 ± 8.7 14.4 ± 3.1 15.6 ± 3.4* 17.5 ± 4.6
Data shown are means ± SEM (n=6 for both groups). RBC: red blood cell. d3, d6, d10, d14 refer to day3
– day14 of the study.
*P < 0.05, significantly different from control values.
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lesions was significantly lower between days 6–14, compared with
controls. The latter finding is in line with the results of our peritoneal
endometriosis model, in which we also observed a reduced micro-
vessel density in SKI-5C-treated lesions on day 7. In contrast, the
lesions of both groups exhibited a comparable density of CD31+
microvessels on day 28. This may be explained by a completed
engraftment process at this late time point. Hence, although we
detected a delayed vascularization under SKI-5C treatment, at the
end of the experiment, the lesions of the two groups no longer dif-
fered in terms of microvessel density.
In adults, physiological angiogenesis typically occurs in the
female reproductive system (Reynolds et al., 2002). In this context,
it should be noted that S1P in follicular fluid stimulated the prolif-
eration of endothelial cells and blood vessel formation during the
development of ovarian follicles (von Otte et al., 2006). Addition-
ally, S1P signalling is involved in the decidualization of human
endometrial stromal cells and the disruption of both SPHK genes
leads to defects in decidual blood vessels (Brünnert et al., 2014;
Mizugishi et al., 2007). Hence, we further investigated whether
SKI-5C treatment induced side effects in the uterus and ovaries.
Notably, we found that these organs did not differ in terms of
morphology, vascularization and proliferative activity between
vehicle- and SKI-5C-treated mice. These preliminary results indicate
that the pharmacological inhibition of SPHK1 suppresses the devel-
opment of endometriotic lesions without affecting the physiological
function of the female reproductive organs. In line with these find-
ings, SPHK1- or SPHK2-knockout mice are viable and fertile with
no obvious phenotypic changes (Kunkel et al., 2013). This indicates
that a reduced synthesis of S1P by loss or suppression of the
activity of one of the two enzymes seems to be compensated by a
higher activity or up-regulation of the non-affected enzyme
(Mizugishi et al., 2005). Based on our results, it is likely that this
compensatory mechanism still works properly in the female repro-
ductive organs during treatment with SKI-5C, while it is disabled
under the pathological conditions of ectopic lesion formation.
Finally, it should be considered that the local synthesis of
oestrogen by overexpression of aromatase (CYP19A1, Cytochrome
P450 Family 19 Subfamiliy A Member 1) and steroidogenic acute
regulatory protein (StaR) plays a major role in the establishment and
progression of endometriosis (Attar et al., 2009). Moreover, the
activation of the two oestrogen receptor isoforms ERα and ERβ is
required for the growth of endometriotic lesions (Burns et al., 2012;
Zhao et al., 2015). Recent studies suggest that oestrogen activates
SPHK1 (Sukocheva et al., 2015). This promotes S1P synthesis and
S1P1 receptor-mediated angiogenesis (Young & Van Brocklyn, 2006).
Hence, although not further analyzed in the present study, it may be
assumed that the inhibition of SPHK1 also suppresses the establish-
ment of endometriotic lesions via blockade of oestrogen receptor
signalling.
In summary, we have demonstrated that the low MW inhibitor of
SPHK1, SKI-5C, inhibits the development and vascularization of endo-
metriotic lesions. Of interest, humanized monoclonal antibodies
against S1P as well as SPHK2 inhibitors are already under clinical
evaluation for the therapy of different cancer types and age-related
macular degeneration (Britten et al., 2017; Pal et al., 2017; Volz &
Pauly, 2015). Our novel findings now indicate that they may be also
promising candidates for the future treatment of endometriosis, if
they are proven to be safe and to exhibit a tolerable range of side
effects.
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